Improved In-house Assay for Lyme Disease Testing – Borrelia VIsE1/pepC10 IgG/IgM Test System

By Albert A. Keshgegian, MD PhD, Medical Director, Main Line Health Laboratories

Effective January 13, 2014, MLHL will be updating our assay for Lyme IgG/IgM antibody testing.  The new ZEUS Borrelia ELISA test system utilizes a dual combination of recombinant VlsE-1 and synthetic pepC10 antigens from Borrelia burgdorferi and simultaneously detects IgG and IgM antibodies in patient sera. This test provides significantly greater specificity (fewer false positives) and greater clinical sensitivity for early acute disease compared with assays which detect antibody responses to only a single antigen. This means confirmatory Western Blots are performed in more appropriate situations, resulting in better patient care and overall cost savings for our patients and our healthcare system.

You do not need to order differently. This updated test will be performed whenever you request Lyme Antibody screen or Lyme Antibody with reflex to Western Blot.  Specimen requirements are unchanged: a gold top serum separator tube is required. Reference ranges remain the same:

 

Interpretation

Range (index)

Negative

≤0.90

Equivocal

0.91 – 1.09

Positive

≥1.10

As with any antibody test, negative results do not totally rule out infection (especially early disease), and the diagnosis should be made in conjunction with history, symptoms, and other lab data.

If you have any questions or concerns, please feel free to contact me at 484-476-3552, or Annemarie Brewer, Immunology Supervisor, at 484-476-8408. 

 

Thank you for your continued support of Main Line Health Laboratories.

 

 

This entry was posted in Clinician News and tagged , , , , , . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *